NL-OMON47074已完成2 期
Targeted therapy with imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period. - ImPACCT
Oncologie0 个研究点目标入组 27 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Histologically proven adenocarcinoma of the colon;
- •Confirmed eligibility for surgery with curative intent;
- •High expression of mesenchymal genes determined with diagnostic qPCR test;
- •WHO performance status 0 or 1.
排除标准
- •The presence of synchronous distant metastases ;
- •Current hospital standard of care dictates that patient should undergo any neoadjuvant therapy;
- •Concurrent participation in another clinical trial using any medicinal product.
研究者
相似试验
进行中（未招募）
不适用
Imatinib therapy for agressive colon cancers.colon cancerEUCTR2014-003965-11-NLniversity Medical Center Utrecht
终止
2 期
Imatinib as Pre-operative Anti-Colon Cancer Targeted TherapyColonic NeoplasmsNCT02685046UMC Utrecht5
已完成
2 期
Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.cutaneous cGVHD.Graft-versus-host reaction or diseaseIRCT201302261030N12Hematology-Oncology and SCT Research Center28
进行中（未招募）
不适用
Imatinib treatment as therapy of neurofibromas in patients with NF1Patients with NF1 and plessiform neurofibromasMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000869-21-ITISTITUTO NEUROLOGICO CARLO BESTA
招募中
1 期
Safety and efficacy of imatinib therapy administered in patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A prospective studyPatients with malignancy, suspected of Pulmonary Tumor Thrombotic Microangiopathy (PTTM)JPRN-jRCTs031210263Hatano Masaru20